

Consensus Statement: Cardiovascular Safety Profile of Acute Treatment of Migraine

Headache

44, 414-425

DOI: [10.1111/j.1526-4610.2004.04078.x](https://doi.org/10.1111/j.1526-4610.2004.04078.x)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 2 | Introduction: Cardiovascular Safety and Triptans in the Acute Treatment of Migraine. <i>Headache</i> , 2004, 44, S1-S4. | 1.8 | 6 |
| 3 | When to Stress Over Triptans: A Markov Analysis of Cardiovascular Risk in Migraine Treatment. <i>Headache</i> , 2004, 44, 652-660. | 1.8 | 6 |
| 4 | Post-triptan era for the treatment of acute migraine. <i>Current Pain and Headache Reports</i> , 2004, 8, 393-398. | 1.3 | 21 |
| 5 | Update on sumatriptan: new progress in migraine treatment. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 349-356. | 0.2 | 8 |
| 6 | Headache. <i>Current Opinion in Neurology</i> , 2005, 18, 279-282. | 1.8 | 3 |
| 7 | New targets in the acute treatment of headache. <i>Current Opinion in Neurology</i> , 2005, 18, 283-288. | 1.8 | 24 |
| 9 | Can we Develop Neurally Acting Drugs for the Treatment of Migraine?. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 741-750. | 21.5 | 64 |
| 10 | Migraine as a Risk Factor for White Matter Lesions, Silent Infarctions, and Ischemic Stroke. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2005, 2, 58-61. | 0.7 | 1 |
| 11 | Adverse reactions related to drugs for headache treatment: clinical impact. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 893-900. | 0.8 | 8 |
| 13 | Migraine headache: Options for acute treatment. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 86-92. | 2.0 | 11 |
| 14 | Non-oral formulations of triptans and their use in acute migraine. <i>Current Pain and Headache Reports</i> , 2005, 9, 206-212. | 1.3 | 20 |
| 15 | Migraine treatment throughout the lifecycle. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 343-353. | 1.4 | 13 |
| 16 | Eletriptan in migraine. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 43-53. | 1.4 | 13 |
| 17 | The Nonpeptide Calcitonin Gene-Related Peptide Receptor Antagonist BIBN4096BS Lowers the Activity of Neurons with Meningeal Input in the Rat Spinal Trigeminal Nucleus. <i>Journal of Neuroscience</i> , 2005, 25, 5877-5883. | 1.7 | 124 |
| 18 | Sinus Headache: A Neurology, Otolaryngology, Allergy, and Primary Care Consensus on Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2005, 80, 908-916. | 1.4 | 97 |
| 19 | Distribution of Zolmitriptan into the CNS in Healthy Volunteers. <i>Drugs in R and D</i> , 2005, 6, 139-147. | 1.1 | 24 |
| 20 | Calcitonin Gene-Related Peptide Antagonists as Treatments of Migraine and Other Primary Headaches. <i>Drugs</i> , 2005, 65, 2557-2567. | 4.9 | 76 |
| 21 | Rizatriptan in migraine. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 597-603. | 1.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 22 | Practical Considerations for the Treatment of Elderly Patients with Migraine. <i>Drugs and Aging</i> , 2006, 23, 461-489. | 1.3 | 22 |
| 23 | An Otolaryngology, Neurology, Allergy, and Primary Care Consensus on Diagnosis and Treatment of Sinus Headache. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 134, 516-523. | 1.1 | 57 |
| 24 | New targets in acute migraine treatment. <i>Future Neurology</i> , 2006, 1, 171-177. | 0.9 | 1 |
| 27 | Towards a Definition of Intractable Headache for Use in Clinical Practice and Trials. <i>Cephalalgia</i> , 2006, 26, 1168-1170. | 1.8 | 185 |
| 28 | Tailoring Management Strategies for the Patient With Menstrual Migraine: Focus on Prevention and Treatment. <i>Headache</i> , 2006, 46, S61-S68. | 1.8 | 16 |
| 29 | Preclinical Neuropharmacology of Naratriptan. <i>CNS Neuroscience & Therapeutics</i> , 2005, 11, 289-316. | 4.0 | 25 |
| 30 | Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 85-94. | 2.3 | 21 |
| 31 | Acute myocardial infarction after sumatriptan administration for cluster headache. <i>Neurological Sciences</i> , 2006, 26, 456-459. | 0.9 | 18 |
| 32 | New and future migraine therapy. , 2006, 112, 199-212. | | 67 |
| 33 | 5-Hydroxytryptamine receptors in the human cardiovascular system. , 2006, 111, 674-706. | | 249 |
| 34 | Migraine: emerging treatment options for preventive and acute attack therapy. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 419-427. | 1.0 | 22 |
| 35 | Sumatriptan: update and review. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1503-1514. | 0.9 | 17 |
| 36 | Optimizing migraine therapy: evidence-based and patient-centered care. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 911-919. | 1.4 | 17 |
| 37 | A Practical Approach to Headache Treatment. <i>Journal of Pharmacy Practice</i> , 2007, 20, 123-136. | 0.5 | 0 |
| 38 | 19 Drugs acting on the cerebral and peripheral circulations. <i>Side Effects of Drugs Annual</i> , 2007, , 202-205. | 0.6 | 0 |
| 39 | Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. <i>Mayo Clinic Proceedings</i> , 2007, 82, 61-68. | 1.4 | 20 |
| 40 | Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine. <i>CNS Drugs</i> , 2007, 21, 73-82. | 2.7 | 31 |
| 41 | Over-the-Counter Triptans for Migraine. <i>CNS Drugs</i> , 2007, 21, 877-883. | 2.7 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 42 | Migraine management in elderly and paediatric patients is difficult, but can usually be managed effectively. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 7-11. | 0.3 | 0 |
| 43 | Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. <i>Mayo Clinic Proceedings</i> , 2007, 82, 61-68. | 1.4 | 25 |
| 44 | Emerging therapies for migraine. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 610-619. | 2.7 | 50 |
| 45 | Understanding the Causes and Prevention of Menstrual Migraine: The Role of Estrogen. <i>Headache</i> , 2007, 47, S86-S94. | 1.8 | 12 |
| 46 | From the Editorial Office. <i>Headache</i> , 2007, 47, 988-989. | 1.8 | 0 |
| 47 | Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. <i>European Journal of Neurology</i> , 2007, 14, 269-275. | 1.7 | 34 |
| 48 | Treatment-Emergent CNS Symptoms Following Triptan Therapy are Part of The Attack. <i>Cephalalgia</i> , 2007, 27, 254-262. | 1.8 | 42 |
| 49 | Migraine and Coronary Heart Disease Mortality: A Prospective Cohort Study. <i>Cephalalgia</i> , 2007, 27, 368-371. | 1.8 | 35 |
| 50 | Almotriptan and zolmitriptan in the acute treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 34-40. | 1.0 | 34 |
| 51 | Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan. <i>Journal of Headache and Pain</i> , 2008, 9, 359-365. | 2.5 | 11 |
| 53 | Pharmacological Characterization of MK-0974 [(3 <i>R</i> ,6 <i>S</i>)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1 <i>H</i> -imidazo[4,5- <i>b</i>]pyridin-5-yl)pyridine-2-carboxamide, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 416-421. | 1.3 | 147 |
| 54 | Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog. <i>British Journal of Pharmacology</i> , 2008, 154, 1254-1265. | 2.7 | 6 |
| 55 | Refractory Headache: Historical Perspective, Need, and Purposes for an Operational Definition. <i>Headache</i> , 2008, 48, 770-777. | 1.8 | 21 |
| 56 | CASE 1: The Well-Intentioned Triptan Prescriber. <i>Headache</i> , 2008, 48, 862-864. | 1.8 | 0 |
| 57 | Sickness Absence Among Female Employees With Migraine and Co-Existing Conditions. <i>Cephalalgia</i> , 2008, 28, 1136-1144. | 1.8 | 12 |
| 58 | Neurovascular pharmacology of migraine. <i>European Journal of Pharmacology</i> , 2008, 585, 313-319. | 1.7 | 11 |
| 59 | Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. <i>Lancet</i> , The, 2008, 372, 2115-2123. | 6.3 | 486 |
| 60 | Use of 5-HT ₁ Agonists in Pregnancy. <i>Annals of Pharmacotherapy</i> , 2008, 42, 543-549. | 0.9 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 61 | Availability of triptans over-the-counter (OTC) for the treatment of migraine has advantages and disadvantages. <i>Drugs and Therapy Perspectives</i> , 2008, 24, 22-23. | 0.3 | 0 |
| 62 | Migraine headache is not associated with cerebral or meningeal vasodilatation—a 3T magnetic resonance angiography study. <i>Brain</i> , 2008, 131, 2192-2200. | 3.7 | 212 |
| 63 | Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. <i>Neurology</i> , 2008, 70, 1304-1312. | 1.5 | 424 |
| 64 | Sumatriptan/naproxen sodium combination for the treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1289-1297. | 1.4 | 9 |
| 65 | Current migraine management – patient acceptability and future approaches. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1043. | 1.0 | 21 |
| 66 | Pharmacological options for treatment of migraine. <i>NursePrescribing</i> , 2009, 7, 300-308. | 0.1 | 0 |
| 67 | Migraine in the triptan era: progresses achieved, lessons learned and future developments. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 559-569. | 0.3 | 23 |
| 68 | Zolmitriptan and the Triptan Era. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2907. | 0.1 | 0 |
| 69 | The triptans. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 649-659. | 1.4 | 12 |
| 70 | Migraine and cardiovascular disease. <i>Neurology</i> , 2009, 72, 1864-1871. | 1.5 | 160 |
| 71 | Randomized, controlled trial of telcagepant for the acute treatment of migraine. <i>Neurology</i> , 2009, 73, 970-977. | 1.5 | 209 |
| 72 | High-Flow Oxygen for Treatment of Cluster Headache. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2451. | 3.8 | 278 |
| 73 | Migraine pathogenesis and state of pharmacological treatment options. <i>BMC Medicine</i> , 2009, 7, 71. | 2.3 | 91 |
| 74 | Examining the binding properties of MK-0974: A CGRP receptor antagonist for the acute treatment of migraine. <i>European Journal of Pharmacology</i> , 2009, 602, 250-254. | 1.7 | 26 |
| 75 | Advances in the basic and clinical science of migraine. <i>Annals of Neurology</i> , 2009, 65, 491-498. | 2.8 | 123 |
| 76 | Ten Years of Rizatriptan: From Development to Clinical Science and Future Directions. <i>Headache</i> , 2009, 49, S3-20. | 1.8 | 16 |
| 77 | Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled Analysis. <i>Headache</i> , 2009, 49, 395-403. | 1.8 | 49 |
| 78 | Acute Myocardial Infarction With Sumatriptan: A Case Report and Review of the Literature. <i>Headache</i> , 2009, 49, 762-764. | 1.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 79 | Margaritasâ€f.â€f.â€f.â€fNot Science. Headache, 2009, 49, 962-964. | 1.8 | 2 |
| 80 | Eletriptan. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1587-1598. | 1.5 | 10 |
| 81 | Neurobiology of migraine. Neuroscience, 2009, 161, 327-341. | 1.1 | 318 |
| 82 | Triptans and troponin: a case report. Orphanet Journal of Rare Diseases, 2009, 4, 15. | 1.2 | 8 |
| 83 | Diagnosis and Management of the Primary Headache Disorders in the Emergency Department Setting. Emergency Medicine Clinics of North America, 2009, 27, 71-87. | 0.5 | 75 |
| 84 | Effect of Calcitonin Gene-Related Peptide Receptor Antagonism on the Systemic Blood Pressure Responses to Mechanistically Diverse Vasomodulators in Conscious Rats. Journal of Cardiovascular Pharmacology, 2010, 56, 518-525. | 0.8 | 23 |
| 85 | Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist. ACS Medicinal Chemistry Letters, 2010, 1, 24-29. | 1.3 | 55 |
| 86 | Triptans: Where Things Stand. Current Treatment Options in Neurology, 2010, 12, 454-463. | 0.7 | 3 |
| 87 | Current practice and future directions in the prevention and acute management of migraine. Lancet Neurology, The, 2010, 9, 285-298. | 4.9 | 203 |
| 88 | Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. Gender Medicine, 2010, 7, 88-108. | 1.4 | 22 |
| 89 | The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects. Archives of Drug Information, 2010, 3, 55-62. | 1.6 | 8 |
| 90 | Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities. Medicinal Research Reviews, 2010, 30, 463-549. | 5.0 | 88 |
| 91 | Headache. Neurotherapeutics, 2010, 7, 149-152. | 2.1 | 2 |
| 92 | Headacheâ€™type adverse effects of NO donors: vasodilation and beyond. British Journal of Pharmacology, 2010, 160, 20-35. | 2.7 | 41 |
| 93 | Episodic migraine headache. , 0, , 54-63. | | 0 |
| 94 | Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Design, Development and Therapy, 2010, 4, 9. | 2.0 | 28 |
| 95 | Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia, 2010, 30, 1443-1457. | 1.8 | 72 |
| 96 | Singleâ€™and Multipleâ€™Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Geneâ€™Related Peptide Receptor Antagonist, in Adults. Journal of Clinical Pharmacology, 2010, 50, 1367-1376. | 1.0 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 97 | Acute Treatment of Migraine Headaches. <i>Seminars in Neurology</i> , 2010, 30, 145-153. | 0.5 | 5 |
| 98 | Sumatriptan therapy for headache and acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2727-2737. | 0.9 | 20 |
| 100 | Current and emerging therapies for migraine prevention and treatment. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 789-809. | 1.0 | 0 |
| 101 | New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. <i>Lancet, The</i> , 2010, 376, 645-655. | 6.3 | 99 |
| 102 | Triptan Therapy in Migraine. <i>New England Journal of Medicine</i> , 2010, 363, 63-70. | 13.9 | 178 |
| 103 | Pitfalls in the Management of Headache in the Emergency Department. <i>Emergency Medicine Clinics of North America</i> , 2010, 28, 127-147. | 0.5 | 23 |
| 104 | Headache and cardiovascular disease: old symptoms, new proposals. <i>Future Cardiology</i> , 2010, 6, 703-723. | 0.5 | 1 |
| 105 | Management of Headache in the Elderly. <i>Drugs and Aging</i> , 2010, 27, 377-398. | 1.3 | 27 |
| 106 | Calcitonin gene-related peptide receptor antagonists for migraine. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 815-823. | 1.9 | 21 |
| 107 | Although treatment may be challenging, many therapies are available to relieve headache in elderly patients. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 13-16. | 0.3 | 0 |
| 108 | Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. <i>Cephalalgia</i> , 2011, 31, 712-722. | 1.8 | 251 |
| 109 | TRPV1 receptor blockade is ineffective in different <i>in vivo</i> models of migraine. <i>Cephalalgia</i> , 2011, 31, 172-180. | 1.8 | 42 |
| 110 | Risks, benefits, and issues in creating a behind-the-counter category of medications. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 26-39. | 0.7 | 10 |
| 111 | Zolmitriptan Induced Acute Coronary Syndrome: A Unique Case. <i>American Journal of Therapeutics</i> , 2011, 18, e153-e156. | 0.5 | 8 |
| 112 | CGRP Receptor Antagonists: Toward a Novel Migraine Therapy. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 1671-1680. | 0.9 | 9 |
| 113 | Long-term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial. <i>Headache</i> , 2011, 51, 73-84. | 1.8 | 82 |
| 114 | Combining Triptans: Patient Satisfaction. <i>Headache</i> , 2011, 51, 135-140. | 1.8 | 4 |
| 115 | The Role of Cardiovascular Screening in Headache Patients. <i>Headache</i> , 2011, 51, 331-337. | 1.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 116 | Migraine Headaches: Diagnosis and Management. Journal of Midwifery and Women's Health, 2011, 56, 282-292. | 0.7 | 5 |
| 117 | Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects. , 2011, 129, 332-351. | | 58 |
| 118 | Symptomatic Treatment of Migraine: When to Use NSAIDs, Triptans, or Opiates. Current Treatment Options in Neurology, 2011, 13, 15-27. | 0.7 | 21 |
| 119 | Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists. Journal of Peptide Science, 2011, 17, 383-386. | 0.8 | 10 |
| 120 | Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2683-2686. | 1.0 | 18 |
| 121 | Current Understanding and Treatment of Headache Disorders. Neurology, 2011, 76, S31-6. | 1.5 | 8 |
| 122 | Are butyrophenones effective for the treatment of primary headache in the emergency department?. Canadian Journal of Emergency Medicine, 2011, 13, 96-104. | 0.5 | 6 |
| 123 | Migraine, cerebrovascular disease and the metabolic syndrome. Annals of Indian Academy of Neurology, 2012, 15, 72. | 0.2 | 16 |
| 124 | CGRP receptor antagonists: an expanding drug class for acute migraine?. Expert Opinion on Investigational Drugs, 2012, 21, 807-818. | 1.9 | 63 |
| 125 | Optimizing triptan therapy in clinical practice. Clinical Practice (London, England), 2012, 9, 329-344. | 0.1 | 1 |
| 127 | Myocardial infarction after taking zolmitriptan. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 167-169. | 0.2 | 3 |
| 128 | Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1043-1050. | 1.5 | 14 |
| 129 | Therapeutic applications for subcutaneous triptans in the acute treatment of migraine. Current Medical Research and Opinion, 2012, 28, 1231-1238. | 0.9 | 6 |
| 132 | Almotriptan. , 0, , 5-7. | | 0 |
| 133 | Eletriptan. , 0, , 158-160. | | 0 |
| 134 | Naratriptan. , 0, , 355-357. | | 0 |
| 135 | Rizatriptan. , 0, , 424-426. | | 0 |
| 136 | Zolmitriptan. , 0, , 493-495. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 137 | Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache. Patient Preference and Adherence, 2012, 6, 27. | 0.8 | 5 |
| 138 | A Randomized, Placebo-Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina. Clinical Pharmacology and Therapeutics, 2012, 91, 459-466. | 2.3 | 54 |
| 139 | Defining and refining 5-HT receptor targets for migraine. Lancet Neurology, The, 2012, 11, 383-384. | 4.9 | 6 |
| 140 | Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease. Headache, 2012, 52, 224-235. | 1.8 | 58 |
| 141 | Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan " Basic Science in Relation to Migraine Treatment. Headache, 2012, 52, 707-714. | 1.8 | 61 |
| 142 | Use of Dopamine Antagonists in Treatment of Migraine. Current Treatment Options in Neurology, 2012, 14, 27-35. | 0.7 | 66 |
| 144 | Activation of 5-hydroxytryptamine _{1B/1D/1F} receptors as a mechanism of action of antimigraine drugs. Expert Opinion on Pharmacotherapy, 2013, 14, 1599-1610. | 0.9 | 32 |
| 145 | Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine. Drugs, 2013, 73, 1339-1355. | 4.9 | 11 |
| 146 | Therapeutic prospects for migraine: Can paradise be regained?. Annals of Neurology, 2013, 74, 423-434. | 2.8 | 22 |
| 147 | Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 637-644. | 1.5 | 8 |
| 148 | QT Prolongation, Torsade de Pointes, Myocardial Ischemia From Coronary Vasospasm, and Headache Medications. Part 1: Review of Serotonergic Cardiac Adverse Events With a Triptan Case. Headache, 2013, 53, 208-216. | 1.8 | 10 |
| 149 | Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine. Cephalalgia, 2013, 33, 1292-1301. | 1.8 | 13 |
| 150 | A Review of Needle-Free Sumatriptan Injection for Rapid Control of Migraine. Headache, 2013, 53, 21-33. | 1.8 | 4 |
| 151 | Novel Approaches in Migraine Treatment. , 2013, , . | | 2 |
| 152 | Targeted Review: Medications for Acute Migraine Treatment. Canadian Journal of Neurological Sciences, 2013, 40, S10-S32. | 0.3 | 2 |
| 153 | Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient. Canadian Journal of Neurological Sciences, 2013, 40, s33-s62. | 0.3 | 2 |
| 154 | Targeted Review: Medications for Acute Migraine Treatment. Canadian Journal of Neurological Sciences, 2013, 40, S10-S32. | 0.3 | 3 |
| 155 | Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient. Canadian Journal of Neurological Sciences, 2013, 40, S33-S62. | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 156 | Headache and vertigo of cervical origin. , 2013, , e22-e38. | | 0 |
| 157 | Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia, 2014, 34, 986-993. | 1.8 | 178 |
| 158 | BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia, 2014, 34, 114-125. | 1.8 | 241 |
| 159 | Triptans for symptomatic treatment of migraine headache. BMJ, The, 2014, 348, g2285-g2285. | 3.0 | 17 |
| 160 | Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology, 2014, 83, 958-966. | 1.5 | 235 |
| 161 | Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database. Cephalalgia, 2014, 34, 5-13. | 1.8 | 38 |
| 162 | Errors in management of acute headache. , 0, , 100-118. | | 0 |
| 163 | Orofacial pain management: current perspectives. Journal of Pain Research, 2014, 7, 99. | 0.8 | 160 |
| 164 | Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. Journal of Headache and Pain, 2015, 16, 535. | 2.5 | 102 |
| 170 | Headache in the elderly. Disease-a-Month, 2015, 61, 249-250. | 0.4 | 3 |
| 171 | Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: preliminary findings from a prospective observational cohort study. Journal of Headache and Pain, 2015, 16, 101. | 2.5 | 85 |
| 172 | Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people. Cephalalgia, 2015, 35, 1172-1180. | 1.8 | 22 |
| 173 | Meningeal Afferent Signaling and the Pathophysiology of Migraine. Progress in Molecular Biology and Translational Science, 2015, 131, 537-564. | 0.9 | 35 |
| 174 | Headache management: pharmacological approaches. Practical Neurology, 2015, 15, 411-423. | 0.5 | 24 |
| 175 | Migraine and risk of stroke in older adults. Neurology, 2015, 85, 715-721. | 1.5 | 53 |
| 176 | Headaches of the Elderly. Current Neurology and Neuroscience Reports, 2015, 15, 30. | 2.0 | 17 |
| 177 | Migraine headaches. Disease-a-Month, 2015, 61, 218-222. | 0.4 | 3 |
| 178 | CGRP Mechanism Antagonists and Migraine Management. Current Neurology and Neuroscience Reports, 2015, 15, 25. | 2.0 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 179 | The therapeutic armamentarium in migraine is quite elderly. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 175-177. | 1.5 | 32 |
| 180 | New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurology, The, 2015, 14, 1010-1022. | 4.9 | 144 |
| 181 | Drug therapy in headache. Clinical Medicine, 2015, 15, 273-279. | 0.8 | 9 |
| 182 | Practical implications of the migraine cardio- and cerebrovascular association: Unmet needs of patients. Cephalalgia, 2015, 35, 140-145. | 1.8 | 10 |
| 183 | Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular Risk. Pain Research and Treatment, 2016, 2016, 1-5. | 1.7 | 7 |
| 184 | A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia, 2016, 36, 887-898. | 1.8 | 218 |
| 185 | Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden. European Journal of Clinical Pharmacology, 2016, 72, 747-754. | 0.8 | 13 |
| 186 | Orofacial Pain. Dental Clinics of North America, 2016, 60, 381-405. | 0.8 | 10 |
| 187 | Considerations for management of migraine symptoms in the primary care setting. Postgraduate Medicine, 2016, 128, 523-537. | 0.9 | 18 |
| 188 | Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients: Table 1. Brain, 2016, 139, 2571-2577. | 3.7 | 40 |
| 189 | Antidepressant Medications. , 2016, , 297-302. | | 0 |
| 190 | Inhaled drug therapy development for the treatment of migraine. Expert Opinion on Pharmacotherapy, 2016, 17, 1733-1743. | 0.9 | 9 |
| 191 | Drugs That May Cause or Exacerbate Heart Failure. Circulation, 2016, 134, e32-69. | 1.6 | 320 |
| 192 | Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis. International Journal of Neuroscience, 2017, 127, 20-27. | 0.8 | 17 |
| 193 | Decompression endoscopic surgery for frontal secondary headache attributed to supraorbital and supratrochlear nerve entrapment: a comprehensive review. European Archives of Oto-Rhino-Laryngology, 2017, 274, 2093-2106. | 0.8 | 11 |
| 194 | Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological Reviews, 2017, 97, 553-622. | 13.1 | 1,168 |
| 195 | The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. Journal of Headache and Pain, 2017, 18, 42. | 2.5 | 48 |
| 196 | Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2017, 57, 1507-1521. | 1.8 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 197 | Extended Long-Term Effects of Cervical Vagal Nerve Stimulation on Headache Intensity/Frequency and Affective/Cognitive Headache Perception in Drug Resistant Complex-Partial Seizure Patients. <i>Neuromodulation</i> , 2017, 20, 375-382. | 0.4 | 7 |
| 198 | Migraine. <i>Lancet</i> , The, 2018, 391, 1315-1330. | 6.3 | 327 |
| 199 | Migraine Therapy: Current Approaches and New Horizons. <i>Neurotherapeutics</i> , 2018, 15, 271-273. | 2.1 | 12 |
| 200 | Is selective 5-HT _{1F} receptor agonism an entity apart from that of the triptans in antimigraine therapy?. , 2018, 186, 88-97. | | 85 |
| 201 | Diagnosis and Management of Headache in Older Adults. <i>Mayo Clinic Proceedings</i> , 2018, 93, 252-262. | 1.4 | 34 |
| 202 | Targeted Acid-Sensing Ion Channel Therapies for Migraine. <i>Neurotherapeutics</i> , 2018, 15, 402-414. | 2.1 | 27 |
| 203 | Side effects associated with current and prospective antimigraine pharmacotherapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 25-41. | 1.5 | 74 |
| 204 | Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. <i>Neurotherapeutics</i> , 2018, 15, 274-290. | 2.1 | 119 |
| 205 | Headache Characteristics and Clinical Features of Elderly Migraine Patients. <i>Headache</i> , 2018, 58, 525-533. | 1.8 | 23 |
| 206 | Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. <i>Cephalalgia</i> , 2018, 38, 959-969. | 1.8 | 153 |
| 207 | Diagnosis and Treatment of Primary Headache Disorders in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2408-2416. | 1.3 | 13 |
| 208 | Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. <i>Journal of Pain Research</i> , 2018, Volume 11, 2221-2227. | 0.8 | 33 |
| 209 | Use and overuse of triptans in Austria – a survey based on nationwide healthcare claims data. <i>Journal of Headache and Pain</i> , 2018, 19, 34. | 2.5 | 17 |
| 210 | Characterization of binding, functional activity, and contractile responses of the selective 5-HT _{1F} receptor agonist lasmiditan. <i>British Journal of Pharmacology</i> , 2019, 176, 4681-4695. | 2.7 | 51 |
| 211 | Practice guideline update summary: Acute treatment of migraine in children and adolescents. <i>Neurology</i> , 2019, 93, 487-499. | 1.5 | 103 |
| 212 | Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). <i>Cephalalgia</i> , 2019, 39, 1343-1357. | 1.8 | 66 |
| 213 | Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine. <i>Cephalalgia</i> , 2019, 39, 1569-1576. | 1.8 | 20 |
| 214 | Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 1081-1090. | 4.9 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 215 | Practice guideline update summary: Acute treatment of migraine in children and adolescents. <i>Headache</i> , 2019, 59, 1158-1173. | 1.8 | 25 |
| 216 | Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-blind Placebo-controlled Phase 3 Clinical Studies. <i>Headache</i> , 2019, 59, 1788-1801. | 1.8 | 31 |
| 217 | Prevalence of migraine in Upper Egypt. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2019, 55, . | 0.4 | 4 |
| 218 | Recent Advances in Pharmacotherapy for Episodic Migraine. <i>CNS Drugs</i> , 2019, 33, 1053-1071. | 2.7 | 26 |
| 219 | Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. <i>Cephalalgia</i> , 2019, 39, 967-977. | 1.8 | 35 |
| 220 | Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine. <i>Frontiers in Pharmacology</i> , 2019, 10, 795. | 1.6 | 20 |
| 221 | Primary headache disorders. <i>Neurology: Clinical Practice</i> , 2019, 9, 233-240. | 0.8 | 25 |
| 222 | Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. <i>Brain</i> , 2019, 142, 1894-1904. | 3.7 | 191 |
| 223 | Gepants for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 555-567. | 1.9 | 106 |
| 224 | Current Approach to Undifferentiated Headache Management in the Emergency Department. <i>Current Pain and Headache Reports</i> , 2019, 23, 26. | 1.3 | 4 |
| 225 | Essential pharmacologic options for acute pain management in the emergency setting. <i>Turkish Journal of Emergency Medicine</i> , 2019, 19, 1-11. | 0.3 | 19 |
| 226 | Cardiac cephalalgia: severe, non-exertional headache presenting as unstable angina. <i>Practical Neurology</i> , 2019, 19, 173-175. | 0.5 | 8 |
| 227 | CGRP – a target for acute therapy in migraine: Clinical data. <i>Cephalalgia</i> , 2019, 39, 420-427. | 1.8 | 27 |
| 228 | Cluster Headache and other Trigeminal Autonomic Cephalgias. <i>Headache</i> , 2020, , . | 0.2 | 3 |
| 229 | Future Therapies for Trigeminal Autonomic Cephalgias: Cluster Headache and Related Conditions. <i>Headache</i> , 2020, , 257-264. | 0.2 | 0 |
| 230 | Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. <i>Cephalalgia</i> , 2020, 40, 19-27. | 1.8 | 35 |
| 231 | Recent Advances in the Management of Cluster Headache. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1. | 0.7 | 2 |
| 232 | Utilization of B12 for the treatment of chronic migraine. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2020, 34, 479-491. | 1.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 233 | Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2020, 34, 1015-1024. | 2.7 | 7 |
| 234 | Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment. <i>Progress in Brain Research</i> , 2020, 255, 99-121. | 0.9 | 7 |
| 235 | Testing rimegepant for migraine—time to revise the trial design? — Authors' reply. <i>Lancet, The</i> , 2020, 395, 1901-1902. | 6.3 | 1 |
| 236 | Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. <i>Medicine in Drug Discovery</i> , 2020, 7, 100053. | 2.3 | 15 |
| 237 | Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials. <i>CNS Drugs</i> , 2020, 34, 463-471. | 2.7 | 18 |
| 238 | Migraine and risk of stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 593-604. | 0.9 | 107 |
| 239 | The Risks or Lack Thereof of Migraine Treatments in Vascular Disease. <i>Headache</i> , 2020, 60, 649-653. | 1.8 | 20 |
| 240 | An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. <i>Pain and Therapy</i> , 2020, 9, 195-215. | 1.5 | 17 |
| 241 | Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. <i>Cephalalgia</i> , 2021, 41, 546-560. | 1.8 | 15 |
| 242 | Optimal dosing of lasmiditan in the management of acute migraine attack: A systematic review and meta-analysis. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 155. | 0.2 | 0 |
| 243 | Prophylaxis of Migraine Protocols and Options. , 2021, , 51-73. | | 0 |
| 246 | Subcutaneous sumatriptan: association with decreases in postoperative pain and opioid use after elective cranial surgery. <i>Journal of Neurosurgery</i> , 2020, , 1-9. | 0.9 | 3 |
| 247 | Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine. <i>Medicine (United States)</i> , 2021, 100, e24741. | 0.4 | 8 |
| 248 | Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. <i>Headache</i> , 2021, 61, 422-429. | 1.8 | 15 |
| 249 | Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review. <i>Clinical Therapeutics</i> , 2021, 43, 654-670. | 1.1 | 1 |
| 250 | Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine. <i>Current Opinion in Neurology</i> , 2021, 34, 330-338. | 1.8 | 7 |
| 251 | Acute Migraine Treatment. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021, 27, 597-612. | 0.4 | 3 |
| 252 | The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. <i>Headache</i> , 2021, 61, 1021-1039. | 1.8 | 286 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. Cephalalgia, 2021, 41, 1499-1505. | 1.8 | 5 |
| 254 | Patients and general practitioners assessment of the main outcomes employed in the acute and preventive treatment of migraine: a cross sectional study. BMC Neurology, 2021, 21, 279. | 0.8 | 2 |
| 255 | Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis. Journal of Clinical Pharmacology, 2021, 61, 1534-1544. | 1.0 | 3 |
| 257 | Serotonin Receptor Ligands: Treatments of Acute Migraine and Cluster Headache. , 2007, , 129-143. | | 18 |
| 258 | Novel synthetic treatment options for migraine. Expert Opinion on Pharmacotherapy, 2021, 22, 907-922. | 0.9 | 15 |
| 259 | Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Current Opinion in Neurology, 2020, 33, 309-315. | 1.8 | 62 |
| 260 | Evolving options for the treatment of cluster headache. Current Opinion in Neurology, 2020, 33, 323-328. | 1.8 | 4 |
| 261 | Update on sumatriptan: new progress in migraine treatment. Therapy: Open Access in Clinical Medicine, 2005, 2, 349-356. | 0.2 | 1 |
| 262 | Rizatriptan in the treatment of migraine. Neuropsychiatric Disease and Treatment, 2006, 2, 247-259. | 1.0 | 24 |
| 263 | Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regeneration Research, 2013, 8, 938-47. | 1.6 | 11 |
| 264 | Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 119-127. | 0.1 | 4 |
| 265 | Efficacy And Safety Of Sumatriptan Plus Naproxen Sodium In The Acute Treatment Of Migraine: Systematic Review And Meta-Analysis Of Randomized Controlled Trials. Internet Journal of Pain, Symptom Control and Palliative Care, 2011, 8, . | 0.2 | 1 |
| 266 | Zolmitriptan-induced acute myocardial infarction. Cardiology Journal, 2012, 19, 76-78. | 0.5 | 9 |
| 267 | The Triptans. , 2007, , 849-857. | | 0 |
| 269 | CGRP Receptor Antagonists for Migraine: Challenges and Promises. , 2010, , 185-197. | | 0 |
| 270 | Loosening the grip of migraine attacks. Pharmacy Today, 2012, 18, 61-72. | 0.0 | 0 |
| 275 | Neurobiological Basis of Migraine. , 0, , 517-556. | | 0 |
| 276 | Emerging Treatment Options for Migraine. Annals of the Academy of Medicine, Singapore, 2020, 49, 226-235. | 0.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 277 | Cefalea ed invecchiamento. , 2008, , 169-186. | | 0 |
| 278 | Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist. <i>Annals of Pharmacotherapy</i> , 2021, 55, 745-759. | 0.9 | 1 |
| 279 | Acute migraine: Current treatment and emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 449-59. | 0.9 | 25 |
| 280 | The pharmacological management of migraine, part 1: overview and abortive therapy. <i>P and T</i> , 2008, 33, 404-16. | 1.0 | 8 |
| 281 | Migraine management. <i>Australian Prescriber</i> , 2020, 43, 148-151. | 0.5 | 0 |
| 282 | Lasmiditan for the Treatment of Migraines With or Without Aura in Adults. <i>Psychopharmacology Bulletin</i> , 2020, 50, 163-188. | 0.0 | 0 |
| 283 | Migraine and pain: Features and treatments. , 2022, , 105-116. | | 0 |
| 284 | Migraine review for general practice. <i>Atencion Primaria</i> , 2022, 54, 102208. | 0.6 | 21 |
| 285 | An Update on Diagnosis and Pharmacologic Therapy for Headache in the Oral and Maxillofacial Surgery Practice. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 83-97. | 0.4 | 0 |
| 286 | Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. <i>Journal of Headache and Pain</i> , 2021, 22, 143. | 2.5 | 6 |
| 287 | Migraine management. <i>Australian Prescriber</i> , 2020, 43, 148-151. | 0.5 | 7 |
| 288 | Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. <i>Lancet Neurology</i> , The, 2022, 21, 284-294. | 4.9 | 59 |
| 289 | Migraine. <i>Nature Reviews Disease Primers</i> , 2022, 8, 2. | 18.1 | 154 |
| 290 | Headache Treatment in Human Immunodeficiency Virus Infection. , 2022, , 115-118. | | 0 |
| 291 | Headache in the Elderly. , 2022, , 195-200. | | 0 |
| 292 | Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. <i>Cephalalgia</i> , 2022, 42, 769-780. | 1.8 | 4 |
| 293 | New Generation Gepants: Migraine Acute and Preventive Medications. <i>Journal of Clinical Medicine</i> , 2022, 11, 1656. | 1.0 | 33 |
| 301 | Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis. <i>Pain and Therapy</i> , 2022, 11, 701-712. | 1.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 303 | Treatment of migraine with monoclonal antibodies. Expert Opinion on Biological Therapy, 2022, 22, 707-716. | 1.4 | 3 |
| 304 | Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments. Current Pain and Headache Reports, 2022, 26, 481-492. | 1.3 | 5 |
| 305 | Serotonin receptor agonist and risk of paresthesia in migraine patients: A dose-response model-based (network) meta-analysis. Annals of Indian Academy of Neurology, 2022, 25, 669. | 0.2 | 0 |
| 306 | Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database – A cohort study. Headache, 2022, 62, 604-612. | 1.8 | 4 |
| 307 | Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert Opinion on Drug Safety, 2022, 21, 1495-1503. | 1.0 | 6 |
| 308 | Safety profile of lasmiditan in patients with migraine in an Asian population. Expert Opinion on Drug Safety, 0, , . | 1.0 | 3 |
| 309 | New Oral Drugs for Migraine. CNS Drugs, 2022, 36, 933-949. | 2.7 | 11 |
| 310 | Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial. Advances in Therapy, 0, , . | 1.3 | 2 |
| 312 | Management of Episodic Migraine with Neuromodulation. Dental Clinics of North America, 2023, 67, 157-171. | 0.8 | 0 |
| 313 | Rimegepant for the treatment of migraine. Health Psychology Research, 2022, 10, . | 0.6 | 4 |
| 314 | Emerging Treatment Options in Migraine. European Medical Journal Neurology, 0, , 50-58. | 0.0 | 0 |
| 315 | Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms. Cells, 2022, 11, 3795. | 1.8 | 9 |
| 316 | MIGRAINE AND CEREBROVASCULAR DISEASES. Bulletin of Problems Biology and Medicine, 2022, 1, 44. | 0.0 | 0 |
| 317 | Utilization patterns, cardiovascular risk, and concomitant serotonergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany. Headache, 2023, 63, 222-232. | 1.8 | 2 |
| 318 | Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium. Cureus, 2023, , . | 0.2 | 1 |
| 319 | Migraine: from pathophysiology to treatment. Journal of Neurology, 2023, 270, 3654-3666. | 1.8 | 16 |
| 320 | Rimegepant 75Âmg in Subjects With Hepatic Impairment: Results of a Phase 1, Openâ€Label, Singleâ€Dose, Parallelâ€Group Study. Clinical Pharmacology in Drug Development, 2023, 12, 790-800. | 0.8 | 3 |
| 324 | Unmet Needs in the Acute Treatment of Migraine. Advances in Therapy, 0, , . | 1.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 327 | The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 17-42. | 1.0 | 0 |